Mizuguchi Hiroyuki

ミズグチヒロユキ | Mizuguchi Hiroyuki

Affiliation and department：
Job title：教授

Research field (1)： Clinical pharmacy

Research keywords (3)：幹細胞生物学 , 分子生物学 , 遺伝子治療学

Papers (345)：

Takeshi Koujima, Hiroshi Tazawa, Takeshi Ieda, Hiroyuki Araki, Takuro Fushimi, Ryohei Shoji, Shinji Kuroda, Satoru Kikuchi, Ryuichi Yoshida, Yuzo Umeda, et al. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Molecular therapy oncolytics. 2020. 17. 107-117
Kanae Kawai, Ryosuke Negoro, Moe Ichikawa, Tomoki Yamashita, Sayaka Deguchi, Kazuo Harada, Kazumasa Hirata, Kazuo Takayama, Hiroyuki Mizuguchi. Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies. Molecular therapy. Methods & clinical development. 2020. 17. 49-57
Masashi Tachibana, Nobumasa Watanabe, Yuzo Koda, Yukako Oya, Osamu Kaminuma, Kazufumi Katayama, Zifei Fan, Fuminori Sakurai, Kenji Kawabata, Takachika Hiroi, et al. Ablation of IL-17A leads to severe colitis in IL-10-deficient mice: implications of myeloid-derived suppressor cells and NO production. International immunology. 2020. 32. 3. 187-201
Nobuhiko Kanaya, Shinji Kuroda, Yoshihiko Kakiuchi, Kento Kumon, Tomoko Tsumura, Masashi Hashimoto, Toshiaki Morihiro, Tetsushi Kubota, Katsuyuki Aoyama, Satoru Kikuchi, et al. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Molecular therapy : the journal of the American Society of Gene Therapy. 2020. 28. 3. 794-804
Ryosuke Negoro, Kanae Kawai, Moe Ichikawa, Sayaka Deguchi, Kazuo Takayama, Hiroyuki Mizuguchi. Establishment of MDR1-knockout human induced pluripotent stem cell line. Drug metabolism and pharmacokinetics. 2020

ｍore...

MISC (80)：

Masahisa Hemmi, Masashi Tachibana, Natsuki Fujimoto, Masaki Shoji, Fuminori Sakurai, Kouji Kobiyama, Ken J. Ishii, Shizuo Akira, Hiroyuki Mizuguchi. Type I IFN signaling induces Th17 cells capable of promoting gut-mucosal CTLs following intramuscular vaccination of an adenovirus vector. CYTOKINE. 2017. 100. 150-150
Kahori Shimizu, Sakurai Fuminori, Shunsuke Iizuka, Masashi Tachibana, Toru Nishinaka, Tomoyuki Terada, Hiroyuki Mizuguchi. Adenovirus Vector-Induced Hepatotoxicity During the Early Phase of Adenoviral Treatment Is Attributed to Inflammatory Cytokine-Induced Leaky Expression of Adenovirus Genes. MOLECULAR THERAPY. 2017. 25. 5. 264-265
F. Sakurai, T. Kaminade, M. Tachibana, H. Mizuguchi. Reovirus-mediated efficient killing of cancer-associated fibroblasts. HUMAN GENE THERAPY. 2016. 27. 11. A86-A86
M. Hemmi, M. Tachibana, N. Fujimoto, M. Shoji, F. Sakurai, K. Kobiyama, K. J. Ishii, S. Akira, H. Mizuguchi. Type I IFN signaling regulates the antigen-specific mucosal immunity following systemic administration of an adenovirus vector vaccine. HUMAN GENE THERAPY. 2016. 27. 11. A146-A146
K. Wakabayashi, M. Machitani, M. Tachibana, F. Sakurai, H. Mizuguchi. Small RNA derived from Adenovirus Virus-Associated RNA II, mivaRNA II, promotes Ad replication via post-transcriptional gene silencing. HUMAN GENE THERAPY. 2016. 27. 11. A174-A174

ｍore...

Education (4)：

- 1996 大阪大学大学院
- 1996 Osaka University Pharmaceutics
- 1991 Osaka University
- 1991 Osaka University

Professional career (1)：

Ph.D (Osaka University)

Work history (13)：

2015/04 - 現在大阪大学国際医工情報センター教授(兼任)
2014/04 - 現在国立研究開発法人医薬基盤・健康・栄養研究所肝細胞分化誘導プロジェクト招へいプロジェクトリーダー(兼任)
2008/10 - 現在大阪大学大学院薬学研究科分子生物学分野教授
2010/11 - 2015/03 大阪大学臨床医工学融合研究教育センター教授(兼任)
2013/04 - 2014/03 独立行政法人医薬基盤研究所創薬基盤研究部肝細胞分化誘導プロジェクト招へいプロジェクトリーダー(併任)

Show all

Awards (14)：

2015 - 大阪大学総長顕彰
2014 - バイオインダストリー協会賞
2014 - 大阪大学総長顕彰
2014 - 文部科学大臣表彰科学技術賞(研究部門)
2013 - 第6回臨床薬理研究振興財団研究大賞

Show all

Association Membership(s) (11)：

日本癌学会 , 日本DDS学会 , 日本薬学会 , 日本遺伝子細胞治療学会 , アメリカ遺伝子細胞治療学会 , The Japan Society of Gene Therapy , International Society for Stem Cell Research , 日本分子生物学学会 , 日本薬物動態学会 , 日本再生医療学会 , 肝細胞研究会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page